Table 2.

Median injection intervals and incidence of AEs by injection group in subjects with ≥2 injection visits in the OLEX (post hoc analysis)

Median injection interval	Number of subjects in interval groupa n (%)	Number of subjects with ≥1 AEb n (%)
6 to ≤10 weeks	22 (23.7)	18/22 (81.8)c
>10 to ≤12 weeks	30 (32.3)	24/30 (80.0)c
>12 to ≤14 weeks	23 (24.7)	22/23 (95.7)c
>14 to 20 weeks	18 (19.4)	12/18 (66.7)c
All intervals	93 (100)	76/93 (81.7)c

Subjects were actively asked at each visit if they experienced drooping of the eyelid, problems with vision, dry eyes, dry mouth, swallowing difficulties, speech problems, shortness of breath, respiratory infection, local weakness, facial weakness, general body weakness, or stomach or bowel disturbances

AE treatment-emergent adverse event, OLEX open-label extension period

^aNinety-three subjects received ≥2 injections and ≤5 injections in the OLEX and were included in this analysis

^bSeventy-six of these 93 subjects experienced ≥1 AE during the OLEX

^cA Chi square test did not show significant differences in the overall occurrence of AEs between the different injection interval groups (p = 0.1229)